Irène Juhan‐vague
#142,806
Most Influential Person Now
Irène Juhan‐vague's AcademicInfluence.com Rankings
Irène Juhan‐vaguemedical Degrees
Medical
#2619
World Rank
#3050
Historical Rank
Cardiology
#243
World Rank
#249
Historical Rank

Download Badge
Medical
Why Is Irène Juhan‐vague Influential?
(Suggest an Edit or Addition)Irène Juhan‐vague's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
- Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease (1997) (669)
- Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. (1988) (593)
- Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. (1996) (591)
- Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. (1986) (463)
- C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study (2003) (409)
- PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events (1997) (399)
- Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis (1987) (376)
- Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. (1993) (365)
- Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. (2000) (362)
- PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences (2006) (358)
- Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk (2003) (358)
- Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin (1989) (333)
- C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet (2007) (332)
- Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 (1988) (326)
- Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis (1991) (314)
- Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. (2009) (304)
- Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. (1984) (265)
- The Effect of Metformin on the Metabolic Abnormalities Associated With Upper-Body Fat Distribution. BIGPRO Study Group (1996) (258)
- Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. (1997) (241)
- Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. (2008) (238)
- Contributions of Depressive Mood and Circulating Inflammatory Markers to Coronary Heart Disease in Healthy European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) (2005) (237)
- Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. (1987) (234)
- Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response (1989) (231)
- Associations of Fibrinogen, Factor VII and PAI-1 with Baseline Findings among 10,500 Male Participants in a Prospective Study of Myocardial Infarction (1998) (228)
- Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study (2004) (220)
- ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome (2007) (218)
- Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. (2004) (215)
- Plasminogen Activator Inhibitor 1 and Atherothrombosis (1993) (210)
- Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits (2002) (205)
- Plasminogen activator inhibitor-1, adipose tissue and insulin resistance (2007) (192)
- Insight into the nature of the CRP-coronary event association using Mendelian randomization. (2006) (191)
- Metabolic syndrome, haemostasis and thrombosis (2008) (183)
- ABCA1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology. (2005) (183)
- Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation (2003) (178)
- Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe (2002) (175)
- Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects (1987) (175)
- Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. (2004) (165)
- Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. (2001) (162)
- Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. (2000) (155)
- The shedding activity of ADAM17 is sequestered in lipid rafts. (2006) (155)
- Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. (1983) (153)
- Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. (1996) (150)
- Ser968Thr Mutation within the A3 Domain of Von Willebrand Factor (VWF) in Two Related Patients Leads to a Defective Binding of VWF to Collagen (2001) (147)
- Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. (1989) (145)
- Platelets Potentiate Brain Endothelial Alterations Induced by Plasmodium falciparum (2006) (145)
- Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. (1998) (143)
- Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. (2000) (139)
- Endothelial cell dysfunction in HIV infection. (1992) (137)
- Fibrinolytic and inflammatory processes in pleural effusions. (1995) (127)
- Plasma cystatin-C and development of coronary heart disease: The PRIME Study. (2006) (126)
- Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. (1998) (126)
- Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. (1995) (124)
- Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium (2009) (122)
- PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. (1999) (122)
- Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls (1994) (120)
- Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss (2001) (120)
- Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. (1991) (117)
- Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. (1997) (116)
- Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. (2000) (115)
- Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. (1999) (110)
- Biological and clinical features of low‐molecular‐weight heparin‐induced thrombocytopenia (2003) (107)
- Plasma TAFI Antigen Variations in Healthy Subjects (2000) (105)
- Increase in Plasma Concentrationof Plasminogen Activator Inhibitor, Fibrinogen, von Willebrand Factor, Factor VIII: Cand in Erythrocyte Sedimentation Rate with Age (1986) (104)
- Development of a Genotype 325–Specific proCPU/TAFI ELISA (2003) (101)
- Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1 (2003) (101)
- Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. (1995) (100)
- Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women (1998) (100)
- Genetic Polymorphisms and Coronary Artery Disease in the South of France (2000) (98)
- Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors (2000) (98)
- Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. (2004) (97)
- TGF-β1 Released from Activated Platelets Can Induce TNF-Stimulated Human Brain Endothelium Apoptosis: A New Mechanism for Microvascular Lesion during Cerebral Malaria1 (2006) (91)
- Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. (2003) (91)
- Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1 (2006) (90)
- The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. (2006) (90)
- Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study (2009) (87)
- Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. (1983) (87)
- Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. (2009) (85)
- Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort (2005) (84)
- Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. (1993) (81)
- The insulin resistance syndrome: implications for thrombosis and cardiovascular disease (2002) (80)
- TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study (2004) (79)
- On the role of coagulation and fibrinolysis in atherosclerosis. (1992) (76)
- Protein S deficiency and HIV infection. (1991) (76)
- Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study (2007) (75)
- Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the erythroid lineage. (2005) (75)
- Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses (2001) (74)
- The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. (1995) (74)
- Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study (2007) (70)
- On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice (2005) (68)
- Adipose Tissue and Atherothrombosis (2003) (68)
- TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study (2005) (67)
- Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity (2001) (66)
- Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol (1985) (66)
- EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. (2005) (66)
- The plasminogen activator inhibitor‐1 −675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study (2003) (65)
- Weak and non‐independent association between plasma TAFI antigen levels and the insulin resistance syndrome (2003) (65)
- The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. (2000) (65)
- Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence (2003) (64)
- Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. (2003) (64)
- Identification of SAP97 as an intracellular binding partner of TACE (2003) (63)
- Contribution of PAI-1 in cardiovascular pathology. (2004) (62)
- Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. (2008) (61)
- Fibrinolysis and risk of coronary artery disease (1996) (61)
- Treatment with metformin of non‐diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial (2000) (60)
- Fibrinolysis and atherosclerosis. (1988) (60)
- Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome (2007) (59)
- Regulation of Fibrinolysis in the Development of Atherothrombosis: Role of Adipose Tissue (1999) (58)
- Pathophysiology of fibrinolysis (1994) (57)
- Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
- Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases (2004) (56)
- Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. (1990) (56)
- Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator (1987) (56)
- Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study (2010) (55)
- Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
- Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe (2004) (52)
- The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polymorphisms): rationale, recruitment, design, dietary intervention and baseline characteristics of participants (2004) (51)
- Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study (2008) (51)
- Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting (2010) (50)
- Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction Study. (2001) (48)
- Fat cell function and fibrinolysis. (2000) (48)
- FHL2 interacts with both ADAM‐17 and the cytoskeleton and regulates ADAM‐17 localization and activity (2006) (48)
- In Vivo Insulin Effect on ATPase Activities in Erythrocyte Membrane From Insulin-Dependent Diabetics (1987) (48)
- Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes (2008) (47)
- Clinical Features in 36 Patients Homozygous for the ARG 506 → GLN Factor V Mutation (1997) (46)
- Plasma Determination of Plasminogen Activator Inhibitor 1 Antigen Must Be Performed in Blood Collected on Antiplatelet/Anticoagulant Mixture (1987) (46)
- Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. (2006) (45)
- Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact (2005) (44)
- Measures to assess the prognostic ability of the stratified Cox proportional hazards model (2009) (44)
- Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity: The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study (2001) (44)
- Formation, Inhibition and Clearance of Plasmin in vivo (2000) (43)
- Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 Levels (2002) (43)
- Upregulation of TNF‐α‐induced ICAM‐1 surface expression by adenylate cyclase‐dependent pathway in human endothelial cells (2005) (42)
- Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels (1992) (42)
- Effect of Atorvastatin on Adhesive Phenotype of Human Endothelial Cells Activated By Tumor Necrosis Factor Alpha (2003) (42)
- Plasma Levels of Free and Total TFPI, Relationship with Cardiovascular Risk Factors and Endothelial Cell Markers (2001) (40)
- Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms (2001) (40)
- Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study (2003) (40)
- Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. (1992) (39)
- Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells (1990) (39)
- Hypofibrinolysis and insulin-resistance. (1991) (38)
- Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. (1993) (37)
- Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. (1990) (36)
- Fibrinolytic function and coronary risk (1999) (36)
- A novel missense mutation shows that GPIbbeta has a dual role in controlling the processing and stability of the platelet GPIb-IX adhesion receptor. (2003) (34)
- The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. (2001) (34)
- ABO Blood Group and Risk of Venous Thrombosis in Heterozygous Carriers of Factor V Leiden (2000) (34)
- Haemostatic parameters and vascular risk (1996) (33)
- Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. (1993) (33)
- Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity (2002) (33)
- Upregulation of TNF-alpha-induced ICAM-1 surface expression by adenylate cyclase-dependent pathway in human endothelial cells. (2005) (31)
- The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. (1990) (31)
- Activation of coagulation in decompression illness. (1998) (30)
- p38 mitogen activated protein kinase controls two successive-steps during the early mesodermal commitment of embryonic stem cells. (2011) (29)
- Effect of 24 Hours of Normoglycaemia on Tissue-Type Plasminogen Activator Plasma Levels in Insulin Dependent Diabetes (1984) (29)
- Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization (1994) (29)
- Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus (2011) (29)
- Up-regulation of PAI-1 Synthesis by Insulin and Proinsulin in HEP G2 Cells but not in Endothelial Cells (1995) (28)
- Association of a sequence variant in DAB2IP with coronary heart disease (2011) (27)
- Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients (2000) (27)
- Protein Z plasma levels are not associated with the risk of coronary heart disease: the PRIME Study (2004) (27)
- [Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)]. (1990) (27)
- Assessment of D-dimer measurement by ELISA or latex methods in deep vein thrombosis diagnosed by ultrasonic duplex scanning (1990) (27)
- Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level. (1997) (27)
- Plasminogen Activator Inhibitor Activity in Various Types of Endogenous Hypertriglyceridemia (1993) (26)
- Released from Activated Platelets Can Induce TNF-Stimulated Human Brain Endothelium Apoptosis: A New Mechanism for Microvascular Lesion during Cerebral Malaria (2005) (26)
- Tiplaxtinin impairs nutritionally induced obesity in mice (2006) (26)
- Fibrinogen, fibrinolysis and diabetes mellitus: a comment (1997) (26)
- Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study (2000) (24)
- Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. (2005) (24)
- Characterization of Epitheloid Cells from Human Omentum: Comparison with Endothelial Cells from Umbilical Veins (1991) (24)
- Iloprost and salvage of a free flap. (1996) (24)
- Up-Regulated Expression of Plasminogen Activator Inhibitor-1 in Hep G2 Cells: Interrelationship between Insulin and Insulin-Like Growth Factor 1 (1995) (22)
- Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. (1992) (22)
- Activation of Plasminogen Activator Inhibitor-1 Synthesis by Phorbol Esters in Human Promyelocyte HL-60 (1999) (22)
- Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. (1991) (22)
- Fibrinolysis in insulin dependent diabetic patients with or without nephropathy (1992) (21)
- New Direct Assay of Free Protein S Antigen Applied to Diagnosis of Protein S Deficiency (1996) (21)
- Bivariate familial correlation analysis of quantitative traits by use of estimating equations: Application to a familial analysis of the insulin resistance syndrome (1999) (21)
- Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels (2010) (20)
- Effect of Atorvastatin on Plasminogen Activator Inhibitor Type‐1 Synthesis in Human Monocytes/Macrophages (2001) (20)
- Proteasome inhibition activates the transport and the ectodomain shedding of TNF-α receptors in human endothelial cells (2005) (20)
- In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial (1994) (20)
- Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction. (2002) (19)
- Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism. (1984) (19)
- 4 Pathophysiology of fibrinolysis (1995) (19)
- Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells. (1990) (19)
- Fibrinogen, obesity and insulin resistance. (1999) (19)
- Relation between Plasma PAI Activity and Adipsin Levels (1995) (18)
- Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies. (1993) (18)
- [Cerebral phlebitis and Crohn disease]. (1992) (18)
- A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease (2003) (18)
- Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR (1999) (18)
- Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille). (1995) (18)
- Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. (1996) (17)
- [From fibrinogen to fibrin and its dissolution]. (2003) (17)
- Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Asssociated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers (2001) (17)
- Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of β-fibrinogen genotype and environmental factors (2004) (17)
- Measurement of Low Molecular Weight Heparin Ex Vivo Activities in Clinical Laboratories Using Various Anti-Xa Assays: Interlaboratory Variability and Requirement for an Agreed Low Molecular Weight Heparin Standard (1987) (17)
- Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. (2003) (17)
- Resistance to Activated Protein C – Diagnostic Strategy in a Laboratory of Haemostasis (1995) (17)
- Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. (1992) (17)
- A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant (1998) (17)
- Unfading acral microlivedo. A discrete marker of thrombotic skin disease associated with antiphospholipid antibody syndrome. (1991) (17)
- Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937 (1996) (15)
- Tumor Necrosis Factor α Up-regulates in an Autocrine Manner the Synthesis of Plasminogen Activator Inhibitor Type-1 during Induction of Monocytic Differentiation of Human HL-60 Leukemia Cells* (2000) (15)
- Leukocyte Activation Study During Occlusive Arterial Disease of the Lower Limb: Effect of Pentoxifylline Infusion (1995) (15)
- Inhibition of p70S6 Kinase during Transforming Growth Factor-β1/Vitamin D3-induced Monocyte Differentiation of HL-60 Cells Allows Tumor Necrosis Factor-α to Stimulate Plasminogen Activator Inhibitor-1 Synthesis* (2001) (14)
- Specificity of an Assay Based on a Factor V-depleted Plasma in Patients Carrying the Arg 506 GIn Mutation (1996) (14)
- Rapid modifications of biophysical and biochemical parameters of red blood cell membrane from insulin dependent diabetics after insulin administration. (1986) (14)
- Chronic plasminogen activator inhibitor‐1 (PAI‐1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung (2007) (13)
- Fibrinolysis and atherothrombosis (1993) (13)
- PLASMA HISTIDINE-RICH GLYCOPROTEIN AND THROMBOPHILIA (1988) (13)
- Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from Type 1 (insulin-dependent) diabetic patients (1986) (12)
- Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus (1997) (12)
- Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women (2006) (12)
- Cutaneous Necrosis Associated with Acquired Severe Protein S Deficiency (1993) (11)
- Modulation of PAI‐1 and proMMP‐9 syntheses by soluble TNFα and its receptors during differentiation of the human monocytic HL‐60 cell line (2003) (11)
- Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease (1988) (11)
- CLINICAL RELEVANCE OF HIGH PAI-1 LEVEL IN PATIENTS WITH IDIOPATHIC/RECURRENT DEEP VENOUS THROMBOSIS (1988) (10)
- ABDOMINAL OBESITY, INSULIN RESISTANCE, AND ALTERATIONS IN HEMOSTASIS (2008) (10)
- Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits. (1982) (10)
- Platelet antibodies in Mediterranean tick typhus. (1985) (10)
- Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. (1991) (9)
- Respective contribution of conventional risk factors and antihypertensive treatment to stable angina pectoris and acute coronary syndrome as the first presentation of coronary heart disease: the PRIME Study (2009) (9)
- A 13 base pair deletion in the GPIbβ gene in a second unrelated Bernard–Soulier family due to slipped mispairing between direct repeats (2004) (9)
- PAI-1, Obesity, and Insulin Resistance (1999) (9)
- Haemostasis in relation to dietary fat as estimated by erythrocyte fatty acid composition: the prime study. (2001) (9)
- [Klinefelter's syndrome and leg ulcers: role of blood coagulation disorders]. (1992) (9)
- Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients. (1999) (8)
- CLINICAL RELEVANCE OF REDUCED t-PA RELEASE UPON VENOUS OCCLUSION IN PATIENTS WITH IDIOPATHIC / RECURRENT DEEP VENOUS THROMBOSIS (1988) (8)
- The Fibrinolytic System and Obesity (2002) (8)
- Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution. (2009) (8)
- The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods (1990) (8)
- MEASUREMENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) IN PLASMA WITH AN ELISA BASED ON TWO MURINE MONOCLONAL ANTIBODIES (1987) (8)
- Protein S deficiency: different biological phenotypes according to the assays used. (1998) (7)
- Measurement of Blood Heparin Levels - variation in Results with Assay Method (1982) (7)
- Purpura Fulminans in a Patient Homozygous for a Mutation in the Protein C Gene - Prenatal Diagnosis in a Subsequent Pregnancy (1996) (7)
- Treatment of Venous Thrombosis and Pulmonary Embolism by Streptokinase (1978) (7)
- Vascular Development and Vessel Remodelling Association between TAFI antigen and Ala 147 Thr polymorphism of the TAFI gene and the angina pectoris incidence The PRIME Study (2003) (6)
- Binding of 99mTc Plasminogen on Fibrin (1981) (6)
- Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells. (2000) (6)
- Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers (2001) (6)
- Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families (2009) (6)
- Intraperitoneal Insulin Administration Does Not Modify Plasminogen Activator Inhibitor 1 Levels in IDDM Patients (1994) (6)
- Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease (1992) (6)
- The effect of plasma proteins and glycosylated fibrinogen on red blood cell aggregation in diabetes (1991) (6)
- Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non cleavable form of TNFα (2004) (6)
- Treatment of deep vein thrombosis with a very low molecular weight heparin (CY 222 - Choay): Thrombolysis and plasma fibrinolytic parameters (1988) (5)
- Catastrophic Arterial Reactivity During Primary Antiphospholipid Syndrome (1999) (5)
- [Disseminated intravascular coagulation masking neonatal hemophilia]. (1991) (5)
- Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study (2010) (5)
- Natural inhibitors of fibrinolysis. (1986) (5)
- PPARα deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance (2004) (5)
- [Heterozygous prothrombin gene mutation G20210A and associated diseases]. (2003) (5)
- [Dyslipidemia, lipid lowering drugs and thrombosis]. (1995) (4)
- Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. (1985) (4)
- Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study) (2004) (4)
- [The significance of the levels of D-dimer in thrombotic conditions]. (1988) (4)
- Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment. (1992) (4)
- Spontaneous adult scurvy in a developed country: new insight in an ancient disease. (1990) (4)
- Fibrinolytic activity in experimental vascular grafts. (1983) (4)
- Plasma Plasminogen Activator Inhibitor Activity in Rats with Nutritionally Induced Insulin Resistance (1995) (3)
- [Endothelium, thrombosis and fibrinolysis]. (1997) (3)
- Anti‐phospholipid/cofactor antibodies in three cases of persistent polyclonal b lymphocytosis (2002) (3)
- Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patients (2004) (3)
- Fibrinolytic anomalies associated with insulin resistance. Effect of metformin. Results of the Bigpro trial (1994) (3)
- Insulin resistance and alterations in the fibrinolytic system (1993) (3)
- [Thromboembolic disease and anomalies of fibrinolysis]. (1986) (2)
- In vitro inhibition of interleukin‐2‐induced defective polymorphonuclear chemotaxis by TNF inhibitor (1993) (2)
- 79. Fibrinolytic factors and the risk of cardiovacular disease (1996) (2)
- [Morphologic study of different types of venous grafts. Correlation trial with parietal fibrinolytic activity]. (1982) (2)
- Relations between hemostatic variables, insulin resistance and inflammation. (2004) (2)
- Variables of the fibrinolytic system: risk indicators for CHD (1997) (2)
- PAI-1 and the Risk of Cardiovascular Disease (1998) (2)
- CLINICAL RELEVANCE OF PLASMA FIBRIN DEGRADATION PRODUCTS DETERMINATION IN PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) (1987) (2)
- Pathophysiology of fibrinolysis. (1995) (2)
- [Immunologic determination of the protein C of coagulation: detection of deficiencies]. (1985) (2)
- [Septicemia, portal thrombosis and congenital protein C deficiency]. (1988) (2)
- Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. (1989) (2)
- Tissue-type plasminogen activator antigen (t-PA Ag) (1992) (2)
- [The link between molecules produced by the adipose tissue, obesity and atherothrombosis]. (2005) (2)
- In vitro Effect of Pentoxifylline on Leukocyte Functions in Myocardial Infarction (1990) (1)
- PARALLEL VARIATIONS OF PLASMA INSULIN, TRIGLYCERIDE AND PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI 1) LEVELS IN OBESE NON DIABETIC SUBJECTS (1987) (1)
- EFFECT OF DIFFERENT HEPARINS ON THROMBOLYSIS WITH t-PA AND scu-PA IN RABBITS WITH EXPERIMENTAL THROMBOSIS (1987) (1)
- Lupus anticoagulants and antiphospholipid antibodies: comparison of clotting tests with an immunological assay. (1990) (1)
- Fibrinolytic a and iinflammatory p processes iin p pleural e effusions (1995) (1)
- [The effect of pentoxifylline and propentofylline on the membrane fluidity of red blood cells in uncontrolled insulin-dependent (type 1) diabetic patients]. (1988) (1)
- DO APTT AND ANTI Ila ACTIVITY PERMIT THE PREDICTION OF THE EFFICIENCY OF HEPARIN THERAPY IN PATIENTS WITH PROXIMAL DEEP VEIN THROMBOSIS? (1987) (1)
- Acquired inhibitor of thrombin associated with an ulcerative colitis (2000) (1)
- Hémophilie acquise par anticorps antifacteur VIIIc. A propos de 3 observations (1983) (1)
- [Evaluation of a functional test in the screening of protein S deficiency]. (2003) (1)
- Erythrocyte rheology in diabetes mellitus (2016) (1)
- [Anti-activator inhibitors of plasminogen]. (1987) (1)
- Hyperactive polymorphonuclear leucocytes migration in patients with familial Mediterranean fever (1996) (1)
- [Erythrocyte and platelet parameters and degree of control of diabetes]. (1982) (1)
- 16 Plasma insulin could regulate plasma PAI-1 concentration (1988) (1)
- A 36 G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women (2018) (1)
- Abstract 1026: Systemic Chemokines Levels and Incident Coronary Heart Disease and Ischemic Stroke Events in Asymptomatic Middle-aged Men: The Prime Study (2009) (1)
- Humans clear active t-pa faster than t-pa/pai-1 complex (1996) (1)
- In vivo cytokines effects on polymorphonuclear cells functions (1992) (1)
- Effect of calcium-chelating and non-chelating anticoagulants on erythrocyte and leucocyte filterability (2016) (1)
- Anticoagulants and erythrocyte filterability. (1984) (1)
- Study of PAI-1 expression during endothelial cell cycle (1994) (0)
- Clinical significance of apolipoprotein B containing lipoprotein particles (1990) (0)
- Tu-W19:2 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome (2006) (0)
- Hemostatic abnormalities associated with obesity and the metabolic syndrome (2005) (0)
- Abstract Poster presentations P-9: Regulation of fibrinolysisCytosolic phospholipase a2 activity in resting and tnf-stimulated cultured human endothelial cells (1994) (0)
- Anticoagulant effects on the measurement of erythrocyte filterability (1985) (0)
- Welcome Address by Prof. A. Serradimigni (1986) (0)
- Erythrocyte deformability and acute phase reactant proteins in arteriosclerosis obliterans patients (2016) (0)
- Treatment of deep vein thrombosis (DVT) with LMWH CY 222. Modifications of biological parameters (1986) (0)
- Post-prandial lipemia in type II — Diabetic patients under optimised metabolic control — Effects of fenofibrate (1995) (0)
- ID: 035 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome (2006) (0)
- Hypofibrinolysis and Hyperinsulinemia (2019) (0)
- [Thromboembolic risk remains uncertain in protein C deficiency]. (1985) (0)
- U937 plasminogen activator inhibitor in the human histiocytic cell line Increase in cytosolic calcium upregulates the synthesis of type 1 (2011) (0)
- Abnormalities of erythrocyte membrane lipids in insulin-dependent diabetics are improved by short term strict control of diabetes (2016) (0)
- Lipopolysaccharide-induced endotoxemia in the mouse is aggrevated by PAI-1 overexpression (2005) (0)
- [Atheroma and antithrombotic agents]. (1992) (0)
- Plasminogen activator inhibitor 1 (PAI-1) gene expression in human megacaryocytes (1994) (0)
- Platelet microparticles: a new player in cerebral malaria pathogenesis (2008) (0)
- Session 7: Regulation and modulation of fibrinolysis39 Insulin increases the synthesis of plasminogen activator inhibitor 1 by an hepatocellular cell line (HEP 62) (1988) (0)
- activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study Fine mapping of quantitative trait nucleotides underlying thrombin (2013) (0)
- Platelet microparticles enhance Plasmodium falciparum‐parasitised red blood cell cytoadherence and activate human brain endothelial cells (2008) (0)
- Plasma plasminogen activator-1 level (PAI-1 L) increase after thrombolytic therapy. A randomized-controlled study with streptokinase (SK) and recombinant tissue-type plasminogen activator (rt-PA) (1996) (0)
- Hemostatic Abnormalities in Diabetes (2003) (0)
- Federal autonomy and the politics of reform: the standardization of mortality statistics in Germany c.1850-1914. (2001) (0)
- [Thrombolytics and their use]. (1999) (0)
- International society for fibrinolysis and thrombolysis (ISFT) minutes of the General Assembly, Florence, 9 June 1997 (1997) (0)
- [Ophthalmic vein thrombosis and G1691A mutation of factor V gene]. (1999) (0)
- « Hémophilie acquisepar anticorps antifacteur VIII c: A propos de 3 observations (1983) (0)
- Contents Vol. 32, 2002 (2002) (0)
- 2.W14.3 Impaired fibrinolysis and the risk of CHD (1997) (0)
- We-W35:2 Inherited and acquired risk factors for juvenile myocardial infarction in an European cohort (2006) (0)
- Contents Vol. 33 (2003) (0)
- [Aneurysm of the abdominal aorta and preoperative disseminated intravascular coagulation]. (1991) (0)
- Biological Variations in t-PA Activator Activity and Antigen (2018) (0)
- Relationship between insulin and IGF-1 in the up-regulation of PAI-1 synthesis in hep G2 cells (1994) (0)
- Monitoring of fibrinolytic treatment with chromogenic substrate assays. (1982) (0)
- [Lipid indicators of vascular risk. A cross-sectional study of a group of coronary patients, a group of subjects with normal coronary angiography and a control group]. (1992) (0)
- [Development in the bone marrow and liver following androgen therapy prolonged by Fanconi's anemia (proceedings)]. (1977) (0)
- [Natural inhibitors of fibrinolysis]. (1986) (0)
- Regulation of PAI-1 in obesity and insulin resistance (1999) (0)
- Principles for the design of rheological studies in diabetes mellitus (2016) (0)
- [Fibrinolytic system and hyperinsulinism]. (1990) (0)
- Molecular-forms of plasminogen-activator inhibitor-1 (pai-1) in plasma (1989) (0)
- PAI-l AND THE RISK OF CARDIOVASCULAR DISEASE (1998) (0)
- Factor XIIIV34L is not an additional genetic risk for venous thrombosis in factor V Leiden carriers. (2001) (0)
- [Acquired hemophilia caused by antifactor VIIIc antibodies. Apropos of 3 cases]. (1983) (0)
- Haemorheological results in a large multicentre study of claudicants treated with ketanserin (2016) (0)
- Subject Index, Vol. 16, Supplement 3, 1986 (1986) (0)
- Contents, Vol. 16, Supplement 3, 1986 (1986) (0)
- Title Page / Table of Contents / Preface (2003) (0)
- The fibrinolytic system in dysmetabolic diseases (1993) (0)
- Vitronectin levels predict metabolic syndrome and diabetes mellitus risks through a PAI-1 dependent mechanism: a 9 year follow-up from the D.E.S.I.R. prospective cohort (2010) (0)
- RELEVANCE OF FREE t-PA ASSAY FOLLOWING VENOUS OCCLUSION IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE (1987) (0)
- B013 Genetic polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the desir prospective study (2009) (0)
- DETERMINATION OF PA INHIBITOR 1 (PA INHIBITOR ACTIVITY AND PA INHIBITOR 1 ANTIGEN) IN PLASMA BEFORE AND AFTER VENOUS OCCLUSION (1987) (0)
- Results Effect of PAI-039 on PAI-1 Secretion by Preadipocytes : Basal (2006) (0)
- Plasminogen activator inhibitor 1 (PAI-1) and insulin-resistance (1990) (0)
- 14 HEMOPHILIA IN FEMALE PHENOTYPIC PATIENTS (1979) (0)
- [abstract] USE OF NEW HEMOSTATIC MARKERS IN DECOMPRESSION ACCIDENTS IN DEEPSEA DIVING (Preliminary results) (1993) (0)
- [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein]. (1987) (0)
- Lupus anticoagulant in silica-induced scleroderma (1992) (0)
- ID: 282 PAI-1 modulates the inflammatory response during Lipopolysaccharide (LPS)-induced endotoxemia. (2006) (0)
- [Aging of the arterial wall: endothelium, thrombosis and fibrinolysis]. (1991) (0)
- Blood Coagulation, Fibrinolysis and Cellular Haemostasis Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus Results from the D.E.S.I.R. prospective cohort (2017) (0)
- [Is hypofibrinolysis a risk factor of thrombosis?]. (1989) (0)
- PAI-1 GENE HAPLOTYPES ARE ASSOCIATED WITH MYOCARDIAL INFARCTION OCCURRENCE IN NON SMOKERS: THE HIFMECH STUDY (2007) (0)
- Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD (2002) (0)
- Fibrinolysis and the metabolic syndrome (2007) (0)
- [Detection of platelet antibodies in idiopathic thrombopenic purpura]. (1987) (0)
- [Factor X deficiency and systemic amylosis]. (1984) (0)
- insulin and acute-phase response Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma (2011) (0)
This paper list is powered by the following services: